Lilly Sees More Dealmaking as GLP-1 Wins Expand Market
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
This analysis highlights how long-term returns vary across index funds, emphasizing the impact on portfolio resilience.
28,357 articlesEli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
As Nvidia signals AI momentum and Marvell rides the wave, investors scan AI bookings and data-center demand to gauge ...
Tech shares wobble as regulatory headlines hit the tape. This piece breaks down the Snap slump, regulatory risks from...
The first watch restaurant stock has cooled off after a strong earnings showing, but the story isn’t just about numbe...
Ford surprised markets with an upward revision to its 2026 guidance after a solid first quarter. This article breaks ...
A new Fed chair steps into a delicate mix of inflation pressures and a resilient job market. This guide breaks down c...
Broadcom is defying a broad market panic as AI-driven demand fuels strong cash flow and robust margins. Here's why in...
As Magnachip heads into 2025 earnings season, investors want clarity on revenue growth, margins, and capital allocati...
Solana (HSDT) 2026 earnings reveal momentum in Q1 amid growing on-chain activity and ecosystem expansion. This guide ...
Five years can change the trajectory of XRP. This article weighs what could push prediction: (ripple) will worth high...
When a space company hits the public markets, unexpected names can move too. This article explains why sandisk stock ...
Nvidia is expanding beyond chips by taking stakes in fellow AI players. This strategic move could quietly power growt...